CANDIDA ALBICANS SURFACE ANTIGENS

长期目标是表征表面抗原 在体外和体内由白色念珠菌表达 开发，确定是否产生单克隆抗体， 这些抗原可用于对C.白色念珠菌，以及 提取和化学表征抗原， 在发病机制中起重要作用。 第一个目标将由 建立表面特异性单克隆抗体库 C.抗原白色念珠菌和使用这些与 免疫胶体金电镜技术。 的 第二个目标是使抗体与许多 在特定条件下生长的真菌菌株。 第三 目的将通过使用突变体来鉴定致病性 决定簇和单克隆抗体来纯化抗原 从细胞壁提取物。 为了诱导对许多表面抗原的抗体应答，小鼠将 对各种细胞壁和其他亚细胞免疫 分数。 一些细胞壁组分将富集菌丝- 特异性抗原 产生的单克隆抗体的特异性 来自致敏脾细胞与浆细胞瘤细胞的融合 将通过交叉免疫电泳技术测定。 各种抗体将用于检测抗原表达 在众多的C.白色念珠菌和其他酵母菌来确定 这些抗体是否能用于C型生物分型白色念珠菌菌株。 此外，对所选细胞上的抗原表达进行表征。 菌株将通过以下酵母和菌丝的发展， 体外和体内的电子显微镜分析水平。 这些研究将提供全面的知识， 念珠菌抗原表达的稳定性或可变性 在该疾病的鼠模型中的球虫病的发展。 一 各种抗原的单克隆抗体库将被 作为这项工作的结果，这些抗体将 用于选择不能产生特定表面的突变体 行列式 将在小鼠中测试这些突变体的毒力 念珠菌病模型，以确定哪些抗原可能相关 to the ability能力to cause引起disease疾病. 这些抗原将被分离 来自野生型菌株并进行化学表征。

The long term objectives are to characterize the surface antigens expressed by Candida albicans during in vitro and in vivo development, determine if monoclonal antibodies raised against these antigens may be used to biotype strains of C. albicans, and extract and chemically characterize antigens which may be important in pathogenesis. The first objective will be done by establishing a bank of monoclonal antibodies specific for surface antigens of C. albicans and use these in conjunction with immunocolloidal gold electron microscopic techniques. The second objective will entail reacting the antibodies with many strains of the fungus grown under specified conditions. The third objective will be done by using mutants to identify pathogenetic determinants and monoclonal antibodies to purify the antigens from cell wall extracts. To induce antibody responses to many surface antigens, mice will be immunized to a variety of cell wall and other subcellular fractions. Some cell wall fractions will be enriched for hyphal- specific antigens. Specificities of monoclonal antibodies resulting from fusions of sensitized spleen cells with plasmacytoma cells will be determined by crossed immunoelectrophoretic techniques. The various antibodies will be used to detect antigen expression among many isolates of C. albicans and other yeasts to determine if the antibodies could be used for biotyping C. albicans strains. In addition, characterization of antigen expression on selected strains will be done by following yeast and hyphal development in vitro and in vivo at the level of electron microscopic analysis. These studies will provide comprehensive knowledge concerning the stability or variability of candidal antigen expression during development of cadidiasis in a murine model of this disease. A bank of monoclonal antibodies to the various antigens will be developed as a result of this work and these antibodies will be used to select mutants unable to produce a particular surface determinant. Virulence of these mutants will be tested in mouse models of candidiasis to ascertain which antigens may be related to the ability to cause disease. Such antigens will be isolated from wild type strains and chemically characterized.